The study supports prior research that found the same thing.

GLP-1 and SGLT2 drugs — could significantly reduce the risk of developing dementia in life, a large new study has found.

None had been diagnosed with Alzheimer disease and related dementias at the start of the study. The researchers discovered that people who took GLP-1 receptor agonists (like Ozempic) or a type of ...

Instead, GLP-1 agonists may help protect the brain by reducing inflammation. Previous research has shown that these drugs can shift immune cells from a pro-inflammatory to an anti-inflammatory ...

A new study, published in JAMA Neurology, finds that people with type 2 diabetes who take two common anti-diabetes medications had a reduced risk of Alzheimer’s and associated dementias.

This summary of health news briefs includes reports on how the U.S.-China trade war impacts drug costs, EU approval of ...

The Department of Commerce launched an investigation on April 1 into the national security impacts of importing drugs and ...

Drugs originally developed to treat type 2 diabetes, particularly GLP-1 receptor agonists such as semaglutide (sold as ...

Dementia, including Alzheimer’s disease and related disorders, is one of the fastest-growing public health concerns globally. It currently affects over 55 million people and is expected to impact 139 ...